Showing results (31-40 of 325) with videos related to

Sort By:
Pageof 33
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1991
An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agentJ Fareed, J M Walenga, L Iyer, et al.
Haemostasis|January 1, 1986
Laboratory studies on the intravenous and subcutaneous administration of PK 10169 in manJ Fareed, J M Walenga, D A Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1986
Coagulant versus amidolytic properties of human and bovine thrombins: implications in standardization and diagnostic usageJ Fareed, J M Walenga, L G Svendsen, et al.
Annals of the New York Academy of Sciences|January 1, 1989
Biochemical and pharmacologic inequivalence of low molecular weight heparinsJ Fareed, J M Walenga, D Hoppensteadt, et al.
Expert Opinion on Investigational Drugs|June 1, 1997
Low molecular weight heparins: a developmental perspectiveJ Fareed, D Hoppensteadt, W Jeske, et al.
Thrombosis Research|December 15, 1988
Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activityJ M Walenga, M Petitou, M Samama, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1996
Are the available low-molecular-weight heparin preparations the same?J Fareed, W Jeske, D Hoppensteadt, et al.
The Canadian Journal of Cardiology|October 21, 1998
Low molecular weight heparins: are they different?J Fareed, D Hoppensteadt, W Jeske, et al.
Critical Reviews in Clinical Laboratory Sciences|January 1, 1983
Synthetic peptide substrates in hemostatic testingJ Fareed, H L Messmore, J M Walenga, et al.
Haemostasis|January 1, 1991
Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudinJ Fareed, J M Walenga, R Pifarre, et al.
Pageof 33